598 related articles for article (PubMed ID: 15329907)
1. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G
Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907
[TBL] [Abstract][Full Text] [Related]
2. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
3. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
4. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
5. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
6. Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML.
Na IK; Kreuzer KA; Lupberger J; Dörken B; le Coutre P
Leuk Res; 2005 Mar; 29(3):343-5. PubMed ID: 15661271
[TBL] [Abstract][Full Text] [Related]
7. Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases.
Miglino M; Varaldo R; Colombo N; Grasso R; Clavio M; Garuti A; Aquino S; Albarello A; Sessarego M; Gobbi M
J Exp Clin Cancer Res; 2006 Sep; 25(3):321-4. PubMed ID: 17167971
[TBL] [Abstract][Full Text] [Related]
8. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
10. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
11. RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia.
Schnittger S; Bacher U; Kern W; Tschulik C; Weiss T; Haferlach C; Haferlach T
Br J Haematol; 2009 Sep; 146(6):665-8. PubMed ID: 19624538
[TBL] [Abstract][Full Text] [Related]
12. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy.
Cilloni D; Saglio G
Semin Hematol; 2003 Apr; 40(2 Suppl 2):37-41. PubMed ID: 12783374
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
15. Prolonged treatment with imatinib mesylate in patients with advanced chronic myeloid leukemia causes a reduction of bcr/abl mRNA levels independent of cytogenetic response.
Cariani E; Capucci M; Micheletti M; Spalenza F; Zanella I; Albertini A; Rossi G
Ann Hematol; 2003 Jun; 82(6):333-5. PubMed ID: 12734675
[TBL] [Abstract][Full Text] [Related]
16. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
Kolb EA; Pan Q; Ladanyi M; Steinherz PG
Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
[TBL] [Abstract][Full Text] [Related]
18. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Cortes J; O'Brien S; Faderl S; Thomas D; Giles F; Rios MB; Shan J; Arlinghaus R
Clin Cancer Res; 2003 Jan; 9(1):160-6. PubMed ID: 12538464
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
Fugazza G; Miglino M; Bruzzone R; Quintino S; Gatti AM; Grasso R; Gobbi M; Frassoni F; Sessarego M
J Exp Clin Cancer Res; 2004 Jun; 23(2):295-9. PubMed ID: 15354415
[TBL] [Abstract][Full Text] [Related]
20. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]